About Fruquintinib
Class: | Antineoplastic agent, VEGFR inhibitor
Use: | Treatment of metastatic colorectal cancer (mCRC) in patients who have received at least two prior systemic therapies
Adult dose: | 5 mg orally once daily, taken continuously for 28-day cycles
Pediatric dose: | Safety and efficacy not established in pediatric patients
Side effects: | Hypertension, fatigue, diarrhea, hand-foot syndrome, decreased appetite, nausea, vomiting, and liver enzyme elevations
Contraindications: | Hypersensiti
Important Warnings
Risk of hypertension, gastrointestinal perforation, and hemorrhage; monitor blood pressure regularly; not recommended for patients with severe cardiovascular disease or recent history of arterial thromboembolic events
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.